Cargando…

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study

The 21-gene Recurrence Score (RS) assay is prognostic and predictive of adjuvant chemotherapy benefit in node positive (N+) breast cancer (BC). We sought to evaluate use patterns of RS assay in N+, ER+/HER2− BC and the impact of RS on recommendations for adjuvant chemotherapy. Patients with T1-T4c,N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peethambaram, Prema P., Hoskin, Tanya L., Day, Courtney N., Goetz, Matthew P., Habermann, Elizabeth B., Boughey, Judy C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648884/ https://www.ncbi.nlm.nih.gov/pubmed/29067357 http://dx.doi.org/10.1038/s41523-017-0044-4

Ejemplares similares

Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB)
por: Mukhtar, Rita A., et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management
por: Tonneson, Jennifer E., et al.
Publicado: (2021)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

ASO Visual Abstract: Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management
por: Tonneson, Jennifer E., et al.
Publicado: (2022)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
por: Pestalozzi, Bernhard C., et al.
Publicado: (2017)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer
por: Yadav, Siddhartha, et al.
Publicado: (2020)

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2013)

ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
por: Stabellini, Nickolas, et al.
Publicado: (2023)

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
por: Cockburn, Jessica G., et al.
Publicado: (2016)

Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2018)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study
por: Mahner, Sven, et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Updated UK Recommendations for HER2 assessment in breast cancer
por: Rakha, Emad A, et al.
Publicado: (2015)

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

High dose simultaneous integrated boost for node positive cervical cancer
por: Jayatilakebanda, Iresha, et al.
Publicado: (2021)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
por: Mukohara, Toru
Publicado: (2011)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
por: James, Rani, et al.
Publicado: (2011)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
por: Norton, Nadine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g1mr2039t5m5huhkm10b3l148i